Gilead's (GILD) Epclusa Granted EC Marketing Authorization as HCV Genotype 1-6 Treatment
Tweet Send to a Friend
Gilead Sciences, Inc. (Nasdaq: GILD) announced that the European Commission has granted marketing authorization for Epclusa (sofosbuvir 400 mg/velpatasvir 100 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
